RT Journal Article
SR Electronic
T1 Kinetical analysis of D-alanine upon oral intake in humans
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.21.24307633
DO 10.1101/2024.05.21.24307633
A1 Kimura, Tomonori
A1 Sakai, Shinsuke
A1 Horio, Masaru
A1 Takahara, Shiro
A1 Ishigo, Shoto
A1 Nakane, Maiko
A1 Negishi, Eiichi
A1 Imoto, Hiroshi
A1 Mita, Masashi
A1 Hamase, Kenji
A1 Higa-Maekawa, Yoko
A1 Kakuta, Yoichi
A1 Mizui, Masayuki
A1 Isaka, Yoshitaka
YR 2024
UL http://medrxiv.org/content/early/2024/05/21/2024.05.21.24307633.abstract
AB D-Alanine, a rare enantiomer of alanine in life, can potentially alleviate the worsening of viral infections and maintain circadian rhythm. This study aimed to analyze the kinetics of D-alanine upon oral intake. Five healthy volunteers were administered D-alanine as a single oral dose at 12,366 or 33,708 μmoL. Upon intake of the lower dose, the plasma level of D-alanine reached its peak concentration of 588.4 ± 40.9 μM with a peak time of 0.60 ± 0.06 h. The plasma level of D-alanine became close to the endogenous level after 24 h. The compartment model estimated the clearance of D-alanine at 12.5 ± 0.3 L/h, or 208 ± 5 mL/min, distribution volume of 8.3 ± 0.7 L and half-life of 0.46 ± 0.04 h. The peak concentration and area under the curve increased proportionally upon intake of the higher dose, while the clearance, distribution volume and half-life did not. The urinary ratio of D-alanine reached its peak of nearly 100%, followed by a slow decline. The peak time of the urinary ratio was 1.15 ± 0.15 h, showing a time lag of blood to urine excretion. Fractional excretion of D-alanine increased from 14.0 ± 5.8% to 64.5 ± 10.3%; the latter corresponded to the urinary clearance of D-alanine as about 77 mL/min for an adult, with a peak time of 1.90 ± 0.56 h. D-Alanine was quickly absorbed and appeared in blood, followed by urinary excretion. This kinetic analysis increases our fundamental knowledge of the oral intake of D-alanine.Competing Interest StatementEmployment: SI, NM, EN, HI, MMit (KAGAMI Inc). Equity: TK, SI, NM, EN, HI, MMit (KAGAMI Inc).Clinical TrialUMIN000050865Funding StatementThis study was funded by Japan Society for the Promotion of Science.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Central Ethics Review Committee of Osaka University gave approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.